Cabaletta Bio (CABA) Cash from Operations (2018 - 2025)
Cabaletta Bio's quarterly Cash from Operations came in at 35343000.0 in Q4 2025, down 52.85% year-on-year from 74965677.09 in Q4 2024, and down 2.42% quarter-over-quarter from 34509000.0 in Q3 2025.
Cabaletta Bio has reported Cash from Operations for 8 years, with the latest figure at 35343000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 52.85% year-over-year to 35343000.0; the trailing twelve-month figure through Dec 2025 stood at 131080000.0 (down 48.58% YoY), and the FY2025 full-year result was 131080000.0, down 48.58% from the prior year.
- Cash from Operations for Q4 2025 stood at 35343000.0, down from 34509000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6580000.0 in Q2 2021, with the low at 35343000.0 in Q4 2025.
- Average Cash from Operations over 5 years is 17667000.0, with a median of 12708500.0 recorded in 2022.
- Year-over-year, Cash from Operations climbed 13.9% in 2021 and sank 90.26% in 2024.
- Tracing CABA's Cash from Operations over 5 years: stood at 10515000.0 in 2021, then retreated by 15.37% to 12131000.0 in 2022, then slumped by 35.59% to 16448000.0 in 2023, then sank by 40.58% to 23122000.0 in 2024, then tumbled by 52.85% to 35343000.0 in 2025.
- The last three Cash from Operations figures came in at 35343000.0 (Q4 2025), 34509000.0 (Q3 2025), and 30426000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -35.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35.34 Mn |
| Dec 31, 2025 | -35.34 Mn |
| Sep 30, 2025 | -34.51 Mn |
| Sep 30, 2025 | -34.51 Mn |
| Jun 30, 2025 | -30.43 Mn |
| Jun 30, 2025 | -30.43 Mn |
| Mar 31, 2025 | -30.80 Mn |
| Mar 31, 2025 | -30.80 Mn |
| Dec 31, 2024 | -23.12 Mn |
| Dec 31, 2024 | -23.12 Mn |
| Sep 30, 2024 | -20.32 Mn |
| Sep 30, 2024 | -20.32 Mn |
| Jun 30, 2024 | -20.79 Mn |
| Jun 30, 2024 | -20.79 Mn |
| Mar 31, 2024 | -23.99 Mn |
| Mar 31, 2024 | -23.99 Mn |
| Dec 31, 2023 | -16.45 Mn |
| Dec 31, 2023 | -16.45 Mn |
| Sep 30, 2023 | -12.60 Mn |
| Sep 30, 2023 | -12.60 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Mar 31, 2023 | -12.61 Mn |
| Mar 31, 2023 | -12.61 Mn |
| Dec 31, 2022 | -12.13 Mn |
| Dec 31, 2022 | -12.13 Mn |
| Sep 30, 2022 | -9.91 Mn |
| Sep 30, 2022 | -9.91 Mn |
| Jun 30, 2022 | -11.53 Mn |
| Jun 30, 2022 | -11.53 Mn |
| Mar 31, 2022 | -12.81 Mn |
| Mar 31, 2022 | -12.81 Mn |
| Dec 31, 2021 | -10.52 Mn |
| Dec 31, 2021 | -10.52 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.58 Mn |
| Jun 30, 2021 | -6.58 Mn |
| Mar 31, 2021 | -8.67 Mn |
| Mar 31, 2021 | -8.67 Mn |
| Dec 31, 2020 | -9.17 Mn |
| Dec 31, 2020 | -9.17 Mn |
| Sep 30, 2020 | -5.02 Mn |
| Sep 30, 2020 | -5.02 Mn |
| Jun 30, 2020 | -7.64 Mn |
| Jun 30, 2020 | -7.64 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Mar 31, 2020 | -4.93 Mn |
| Dec 31, 2019 | -7.88 Mn |
| Dec 31, 2019 | -7.88 Mn |
| Sep 30, 2019 | -2.08 Mn |
| Sep 30, 2019 | -2.08 Mn |
| Jun 30, 2019 | -3.82 Mn |
| Jun 30, 2019 | -3.82 Mn |
| Mar 31, 2019 | -2.27 Mn |
| Mar 31, 2019 | -2.27 Mn |
| Dec 31, 2018 | -1.91 Mn |
| Dec 31, 2018 | -1.91 Mn |